

Table 1. Demographic and general IBD data.

	Total	UC	CD
Patient count	162 (100 %)	117 (72.2%)	45 (27.8%)
<i>Male</i>	93 (57.4%)	67 (57.3%)	26 (57.8%)
<i>Female</i>	69 (42.6%)	50 (42.7%)	19 (42.2%)
Mean age (SD)	42.5 (14.2)	43.1 (14)	40.9 (14.9)
Illness duration in years (SD)	9 (6.8)	9.5 (7.0)	7.7 (6.1)
<i><5 years</i>	46 (28.4%)	31 (26.5%)	15 (33.3%)
<i>5-10 years</i>	53 (32.7%)	35 (29.9%)	18 (40%)
<i>>10 years</i>	63 (38.9%)	51 (43.6%)	12 (26.7%)
Used systemic treatment	155 (95.7%)	112 (95.7%)	43 (95.6%)
Biological therapy	82 (50.6%)	50 (42.7%)	32 (71.1%)
<i>Infliximab/adalimumab</i>	46 (56.1%)	25 (50.0%)	21 (65.6%)
<i>Vedolizumab</i>	13 (15.9%)	11 (22.0%)	2 (6.3%)
<i>Ustekinumab</i>	9 (11.0%)	3 (6.0%)	6 (18.8%)
<i>Mirikizumab (clinical trial)</i>	11 (13.4%)	8 (16.0%)	3 (9.4%)
<i>Risankizumab (clinical trial)</i>	3 (3.7%)	3 (6.0%)	0 (0.0%)
JAK inhibitors	6 (3.7%)	5 (4.27%)	1 (2.22%)
<i>Tofacitinib</i>	4 (66.7%)	4 (80.0%)	0 (0%)
<i>Upadacitinib (clinical trial)</i>	2 (33.3%)	1 (20.0%)	1 (100%)

* IBD – inflammatory bowel disease; UC – ulcerative colitis; CD – Crohn’s disease; SD –standard deviation; JAK inhibitors – a Janus kinase inhibitor.

Table 2. The prevalence of skin lesions reported by inflammatory bowel disease patients.

Skin lesions	Total n = 162	Ulcerative colitis n = 117	Crohn's disease n = 45
Psoriasis	13 (8,0%)	11 (9,4%)	2 (4,4%)
Erythema nodosum	9 (5,6%)	4 (3,4%)	5 (11,1%)
Pyoderma gangrenosum	6 (3,7%)	5 (4,3%)	1 (2,2%)
Acne	6 (3,7%)	5 (4,3%)	1 (2,2%)
Vitiligo	3 (1,9%)	3 (2,6%)	0 (0%)
Epidermolysis bullosa acquisita	1 (0,6%)	1 (0,9%)	0 (0%)
Vasculitis	1 (0,6%)	1 (0,9%)	0 (0%)
Sweet syndrome	0 (0%)	0 (0%)	0 (0%)
Hidradenitis suppurativa	0 (0%)	0 (0%)	0 (0%)
<i>Others:</i>			
Seborrheic dermatitis	3 (1,9%)	3 (2,6 %)	0 (0%)
Atopic dermatitis	4 (2,5%)	4 (3,4%)	0 (0%)
Unspecified dermatitis	11 (6,8%)	8 (6,8%)	3 (6,7%)
Others skin lesions	17 (10,5%)	13 (11,1%)	4 (8,9%)

Table 3. The prevalence of skin lesions among different types of Crohn's disease.

Skin lesions	Ileitis	Colitis	Ileocolitis
Erythema nodosum	1 (5,9%)	3 (27,3%)	1 (5,9%)
Pyoderma gangrenosum	0 (0%)	1 (9,1%)	0 (0%)
Acne	0 (0%)	0 (0%)	1 (5,9%)
Psoriasis	0 (0%)	0 (0%)	2 (11,8%)
Vitiligo	0 (0%)	0 (0%)	0 (0%)
Epidermolysis bullosa acquisita	0 (0%)	0 (0%)	0 (0%)
Vasculitis	0 (0%)	0 (0%)	0 (0%)
<i>Others:</i>			
Atopic dermatitis	0 (0%)	0 (0%)	0 (0%)
Seborrheic dermatitis	0 (0%)	0 (0%)	0 (0%)
Unspecified dermatitis	1 (5,9%)	1 (9,1%)	1 (5,9%)
Others skin lesions	2 (11,8%)	0 (0%)	2 (11,8%)




Figure 1. Skin lesions distribution between ulcerative colitis types.

* $p = 0.01$ between the proctitis and pancolitis groups.

Skin lesions among different ulcerative colitis types




Figure 2. The prevalence of skin lesions among different types of ulcerative colitis.




Figure 3. The distribution of skin lesions according to the time of their onset.

* IBD – inflammatory bowel disease.